|
|
|
Sight Sciences Inc (NASDAQ: SGHT) |
|
|
|
|
Select the Financial Report:
|
|
Select the Period:
|
|
Description of Sight Sciences Inc's Business Segments
Sight Sciences Inc. is a medical technology company focused primarily on developing innovative solutions for the treatment of chronic eye conditions, particularly glaucoma and dry eye disease. The company aims to transform the standard of care by integrating advanced technology into minimally invasive procedures, thereby improving patient outcomes and enhancing the performance of healthcare providers. Below are extensive descriptions of the segments, products, and services offered by Sight Sciences Inc.
Segments
1. Glaucoma:
- This segment focuses on developing minimally invasive surgical (MIS) devices designed for the treatment of glaucoma, a condition characterized by increased intraocular pressure that can lead to optic nerve damage and irreversible vision loss.
- The company's innovative approach allows for effective and efficient drainage of excess aqueous humor, helping to lower intraocular pressure without the need for traditional surgical techniques.
2. Dry Eye Disease:
- The dry eye segment concentrates on addressing the various causes and symptoms of dry eye disease, a common condition that arises when the eyes do not produce enough tears or the tears evaporate too quickly.
- Products in this segment aim to restore balance to the tear film and alleviate discomfort for patients suffering from this chronic condition.
Products
1. iStent Infinite:
- This is a micro-invasive glaucoma surgery (MIGS) device designed to lower intraocular pressure in patients with mild to moderate glaucoma.
- The iStent Infinite allows for the creation of a permanent opening in the eye's drainage system while preserving the natural anatomy of the eye, which can facilitate fluid outflow and reduce pressure effectively.
2. iPrv' (iPulse):
- The iPrv device represents a new class of treatment for dry eye disease that uses a novel pulsatile technology.
- It is designed to enhance the natural production of tears through stimulation of the meibomian glands, addressing one of the underlying causes of dry eye symptoms.
3. Surround' System:
- This is a device designed for managing glaucoma that incorporates both surgical and therapeutic features.
- The Surround System promotes effective outflow of aqueous humor to manage intraocular pressure while allowing for ergonomic handling and ease of use during procedures.
4. TearCare':
- This system is targeted at patients suffering from meibomian gland dysfunction (MGD), the leading cause of evaporative dry eye disease.
- The TearCare system gently heats the eyelids to facilitate the expression of obstructed meibomian glands, restoring the lipid layer of the tear film and improving ocular comfort.
Services
1. Clinical Support and Education:
- Sight Sciences Inc. offers extensive educational resources and clinical support to healthcare professionals. This includes training on the use of their technology, surgical techniques, and best practices for patient care.
- The aim is to ensure that healthcare providers are well-equipped to offer the newest solutions effectively and safely.
2. Research and Development (R&D):
- The companys R&D division is dedicated to continuous innovation in eye care technology. This segment conducts clinical trials, gathers real-world evidence, and engages in partnerships with academic institutions and researchers to advance the field of ophthalmology.
- Sight Sciences places a strong emphasis on understanding patient needs and developing products that meet those demands.
3. Patient Engagement Programs:
- The company provides resources designed to improve patient education about eye health and the management of chronic conditions like glaucoma and dry eye.
- Engagement programs may include informational materials, online resources, and support networks to assist patients in understanding their conditions and available treatments.
Overall, Sight Sciences Inc. stands out for its commitment to enhancing patient care through innovative surgical and therapeutic interventions in ophthalmology. The company seeks not just to develop cutting-edge products but also to facilitate education and support for both healthcare providers and patients, thereby fostering a holistic approach to eye health.
Composition of Sight Sciences Inc Revenues by
Segments |
| |
| Surgical Glaucoma |
|
 100.12 % |
of total Revenue |
| Dry Eye |
|
2.3 % |
of total Revenue |
Q1 three months ended (Mar 31 2025)
|
| Revenues by Business Segments |
Revenues
(in millions $) |
%
(of total Revenues) |
| Surgical Glaucoma |
17.11 |
100.12 % |
| Dry Eye |
0.39 |
2.3 % |
| Total |
17.09 |
100 % |
Q1 three months ended (Mar 31 2025)
|
| Revenue Growth rates by Segment |
Y/Y Revenue
% |
Q/Q Revenue
% |
| Surgical Glaucoma |
-6.26 % |
- |
| Dry Eye |
-60.91 % |
- |
| Total |
-7.46 % |
-78.44 % |
Q1 three months ended (Mar 31 2025)
|
| Income by Business Segments |
Income
(in millions $) |
%
(Profit Margin) |
| Surgical Glaucoma |
14.82 |
86.57 % |
| Dry Eye |
0.28 |
70.56 % |
| Total |
-14.15 |
- |
Q1 three months ended (Mar 31 2025)
|
| Income Growth rates by Segment |
Y/Y Income
% |
Q/Q Income
% |
| Surgical Glaucoma |
-7.68 % |
- |
| Dry Eye |
-34.43 % |
- |
| Total |
- |
- |
Annual Report on Sight Sciences Inc Divisions, Sales by Country |
| |
| Surgical Glaucoma |
|
95.73 % |
of total Revenue |
| Dry Eye |
|
5 % |
of total Revenue |
Twelve months ended 2024
|
| SGHT s Annual Revenue by Geography and Business Segments |
Sales
(in millions $) |
%
(of total Sales) |
| Surgical Glaucoma |
75.90 |
95.73 % |
| Dry Eye |
3.96 |
5 % |
| Total |
79.29 |
100 % |
Twelve months ended 2024
|
| SGHT s Annual Income by Country and Business Segments |
Income
(in millions $) |
%
(Profit Margin) |
| Surgical Glaucoma |
66.45 |
87.55 % |
| Dry Eye |
1.83 |
46.19 % |
| Total |
-51.51 |
- |
Twelve months ended 2024
|
| Annual Revenue and Income Growth by Country and Business Segments |
% Y/Y Sales Growth |
% Y/Y Income Growth |
| Surgical Glaucoma |
2.14 % |
1.49 % |
| Dry Eye |
-41.24 % |
-50.45 % |
| Total |
-1.11 % |
- |
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
